Company profile: Alkahest
1.1 - Company Overview
Company description
- Provider of blood-derived therapies for neurological diseases focused on age-related cognitive decline. Offers AKST4290, an orally administered drug targeting CCR3 for wet AMD and Parkinson's; GRF6019 and GRF6021, selected human plasma fractions for Alzheimer's and Parkinson's with cognitive impairment; AKST1210 to remove beta-2 microglobulin and improve cognitive impairment in end-stage renal disease; and novel plasma proteome factor candidates. Collaborates with Grifols.
Products and services
- GRF6019: A selected human plasma fraction developed to treat mild to moderate Alzheimer’s disease by replenishing regenerative chronokines identified in blood plasma, plasma-derived
- GRF6021: A selected human plasma fraction aimed at treating Parkinson’s disease with cognitive impairment and aiding postoperative recovery, blood-based
- Novel Factors: Undisclosed therapeutic candidates targeting novel factors identified in the plasma proteome for age-related diseases, leveraging proteomic discovery to create blood-derived therapeutics, proteomics-driven
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alkahest
Pharnext
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical therapeutics for severe neurodegenerative diseases, developing PXT3003 for Charcot-Marie-Tooth disease type 1A using its Pleotherapy approach (Phase III), and PXT864, a fixed-dose combination of baclofen and acamprosate progressing to Phase 2a in ALS; also sponsors CMT&Me, an app-based international study of CMT patient lifestyles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharnext company profile →
Avation
HQ: United States
Website
- Description: Provider of wearable tibial neuromodulation systems for treating urinary incontinence and urgency from overactive bladder, delivered via a garment and integrated with a mobile app for therapy management and personalized energy delivery, including an eDiary to track patient activity and progress toward goals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avation company profile →
Impel Pharmaceuticals
HQ: United States
Website
- Description: Provider of intranasal drug treatments for central nervous system disorders, offering Trudhesa, a dihydroergotamine mesylate nasal spray for the acute treatment of migraine with or without aura in adults, and its proprietary Precision Olfactory Delivery (POD) technology targeting the vascular-rich upper nasal space for rapid absorption and consistent bioavailability, alongside partnerships to explore applications with small and large molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impel Pharmaceuticals company profile →
Zalicus
HQ: United States
Website
- Description: Provider of discovery and development of novel-target pain therapies, including a calcium channel modulator for chronic and acute inflammatory pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zalicus company profile →
Rapport Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for neurological disorders, leveraging a RAP Technology Platform to discover and develop small-molecule therapies targeting specific neuronal receptor complexes. Programs include TARPγ8 AMPAR small molecules in clinical development for epilepsy with potential in pain and bipolar disorder, and discovery-stage nAChR modulators for chronic pain and hearing disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapport Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alkahest
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alkahest
2.2 - Growth funds investing in similar companies to Alkahest
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alkahest
4.2 - Public trading comparable groups for Alkahest
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →